Plant ID: NPO11583
Plant Latin Name: Calycanthus floridus
Taxonomy Genus: Calycanthus
Taxonomy Family: Calycanthaceae
NCBI TaxonomyDB:
3429
Plant-of-the-World-Online:
42922-2
Antiperiodic; Antispasmodic; Cardiac; Disinfectant; Diuretic; Emetic; Ophthalmic; Skin
United States; Georgia; China; South Africa
ACHE; | |
FLT3; MAPK1; CDK8; CSNK2A1; | |
CA2; CA12; CA14; CA7; CA4; | |
ESR2; | |
HSD17B1; GFER; NOX4; | |
MMP9; MMP1; MMP12; MMP2; | |
HIF1A; NFKB1; | |
THPO; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
Protein Kinase | CDK8 | Cell division protein kinase 8 | P49336 | CHEMBL5719 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 8.740E-12 | 1.342E-07 | CA12, CA14, CA2, CA4, CA7 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.513E-11 | 1.824E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, NOX4 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 5.385E-10 | 2.931E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 3.079E-09 | 1.117E-05 | CA12, CA14, CA2, CA4, CA7 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.519E-08 | 3.760E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
MF | GO:0005488; binding | GO:0020037; heme binding | 1.554E-08 | 3.760E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, NOX4 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.244E-08 | 4.428E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 9.504E-08 | 1.150E-04 | HIF1A, MMP1, MMP12, MMP2, MMP9 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.475E-07 | 1.626E-04 | CA12, CA2, CA4, CA7 |
BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 2.716E-07 | 2.571E-04 | HIF1A, MMP1, MMP12, MMP2, MMP9 |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 6.496E-07 | 5.642E-04 | CA12, CA2, CA4, CA7, ESR2, MMP1, MMP12, MMP2, MMP9 |
BP | GO:0032502; developmental process | GO:0048513; animal organ development | 1.623E-06 | 1.124E-03 | ACHE, CA2, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, FLT3, GFER, HIF1A, MAPK1 |
BP | GO:0008152; metabolic process | GO:0030574; collagen catabolic process | 1.651E-06 | 1.124E-03 | MMP1, MMP12, MMP2, MMP9 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.093E-06 | 1.302E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
BP | GO:0009987; cellular process | GO:0022617; extracellular matrix disassembly | 3.618E-06 | 1.969E-03 | MMP1, MMP12, MMP2, MMP9 |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 3.766E-06 | 2.000E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 5.222E-06 | 2.419E-03 | CA2, CA7 |
BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 5.841E-06 | 2.650E-03 | CYP1A1, CYP1B1, FLT3, MAPK1, NFKB1, NOX4 |
BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 9.491E-06 | 3.974E-03 | CYP1A2, MAPK1, MMP9 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.044E-05 | 4.132E-03 | CYP1A1, CYP1A2 |
MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 1.260E-05 | 4.426E-03 | CYP19A1, CYP1A1, CYP2C19 |
BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 1.429E-05 | 4.815E-03 | CSNK2A1, FLT3, HIF1A, MAPK1, MMP12, MMP2, MMP9, THPO |
BP | GO:0009987; cellular process | GO:0009967; positive regulation of signal transduction | 1.437E-05 | 4.815E-03 | CSNK2A1, CYP1B1, FLT3, HIF1A, MAPK1, MMP12, MMP9, NFKB1, NOX4, THPO |
BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 1.563E-05 | 5.081E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, GFER, HSD17B1, NOX4 |
MF | GO:0003824; catalytic activity | GO:0004222; metalloendopeptidase activity | 1.611E-05 | 5.158E-03 | MMP1, MMP12, MMP2, MMP9 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.605E-05 | 7.988E-03 | CYP1A2, CYP2C19 |
MF | GO:0003824; catalytic activity | GO:0017171; serine hydrolase activity | 3.330E-05 | 9.598E-03 | ACHE, MMP1, MMP12, MMP2, MMP9 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.511E-11 | 1.980E-09 | CA12, CA2, CA4, CA7, CA14 |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.080E-08 | 7.071E-07 | HSD17B1, CYP1A2, CYP1A1, CYP1B1, CYP19A1 |
09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 5.470E-07 | 1.433E-05 | FLT3, MMP1, MMP2, MAPK1, HIF1A, MMP9, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 2.199E-07 | 9.602E-06 | MMP1, MMP2, MAPK1, MMP9 |
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 4.961E-07 | 1.433E-05 | HSD17B1, CYP1A1, CYP1B1, CYP19A1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 7.766E-06 | 1.453E-04 | MMP2, MAPK1, MMP9, ESR2 |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 3.663E-06 | 7.997E-05 | CYP1A2, CYP1A1, CYP1B1, CYP2C19 |
09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 1.866E-05 | 3.056E-04 | CYP1A2, CYP1A1, CYP1B1 |
09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 5.447E-05 | 7.928E-04 | FLT3, MAPK1, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 1.293E-04 | 1.303E-03 | MMP2, MAPK1, HIF1A, MMP9 |
09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 1.096E-04 | 1.247E-03 | MAPK1, NFKB1, ESR2 |
09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 8.841E-05 | 1.158E-03 | FLT3, MAPK1, HIF1A |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 2.987E-04 | 2.763E-03 | MMP2, MAPK1, NFKB1 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.142E-04 | 1.247E-03 | CYP1A2, CYP1A1, CYP1B1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04668 | TNF signaling pathway | 3.838E-04 | 3.115E-03 | MAPK1, MMP9, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 3.164E-04 | 2.763E-03 | MAPK1, HIF1A, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 5.505E-04 | 4.006E-03 | CYP1B1, MAPK1, MMP9, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 8.760E-04 | 5.738E-03 | MAPK1, MMP9, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 1.601E-03 | 9.984E-03 | FLT3, MMP9, NFKB1 |
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 6.457E-04 | 4.452E-03 | CYP1A2, CYP2C19 |
09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 4.043E-04 | 3.115E-03 | CA2, CA4 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
NA: NA | Upper abdominal bloating | NA | ACHE; |
C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1; |
I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1; |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; |
C00-D49: Neoplasms | Breast cancer | C50 | FLT3; CYP19A1; |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MMP12; |
C00-D49: Neoplasms | Cancer | C00-C96 | CSNK2A1; NFKB1; FLT3; ACHE; HIF1A; MMP9; MAPK1; MMP2; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MMP1; |
J00-J99: Diseases of the respiratory system | Asthma | J45 | MMP12; |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; |
C00-D49: Neoplasms | CLL | NA | FLT3; |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; MMP9; |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; |
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | FLT3; HIF1A; MMP9; MAPK1; MMP2; |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; |
C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12; |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2; |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
NA: NA | Edema | NA | CA2; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | MMP12; |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
NA: NA | GIST | NA | FLT3; |
C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
C00-D49: Neoplasms | AML | NA | FLT3; |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; MMP2; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE; |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MMP12; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |